Clinical trial
Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
NCT00303966 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00303966 |
|---|---|
| Title | Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia |
| Official title | A Phase II Study of BAY 43-9006 in Relapsed Chronic Lymphocytic Leukemia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | sorafenib tosylate |
| Enrollment | 5 |
| Start date | Nov 1, 2005 |
| Primary completion | May 1, 2011 |
| Completion | May 1, 2011 |
| First posted | Mar 17, 2006 |
| Last update posted | May 7, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: